Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 4,825 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 4,825 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $16.26, for a total value of $78,454.50. Following the completion of the sale, the director now directly owns 3,702,595 shares of the company’s stock, valued at approximately $60,204,194.70. The trade was a 0.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tyra Biosciences Trading Down 4.8 %

Shares of TYRA opened at $14.65 on Thursday. The company has a market capitalization of $741.29 million, a price-to-earnings ratio of -9.10 and a beta of 1.04. Tyra Biosciences, Inc. has a 12 month low of $12.48 and a 12 month high of $29.60. The stock has a 50 day moving average of $15.34 and a 200 day moving average of $19.06.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, equities research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new stake in Tyra Biosciences in the 4th quarter worth approximately $149,000. JPMorgan Chase & Co. grew its holdings in Tyra Biosciences by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock worth $8,667,000 after acquiring an additional 3,896 shares during the last quarter. Franklin Resources Inc. purchased a new position in Tyra Biosciences during the 3rd quarter valued at about $278,000. Barclays PLC increased its stake in shares of Tyra Biosciences by 200.5% during the third quarter. Barclays PLC now owns 37,625 shares of the company’s stock valued at $884,000 after buying an additional 25,106 shares during the period. Finally, State Street Corp raised its holdings in Tyra Biosciences by 4.4% in the 3rd quarter. State Street Corp now owns 384,732 shares of the company’s stock worth $9,045,000 after purchasing an additional 16,248 shares in the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. UBS Group started coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Monday, January 13th. Wedbush reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.